880 results on '"Barreiro, Eliezer J."'
Search Results
2. N-acylhydrazone derivative modulates cell cycle regulators promoting mitosis arrest and apoptosis in estrogen positive MCF-7 breast cancer cells
3. Regioselective Nucleophilic Aromatic Substitution: Theoretical and Experimental Insights into 4-Aminoquinazoline Synthesis as a Privileged Structure in Medicinal Chemistry.
4. Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
5. Novel Agonists of Adenosine Receptors in Animal Model of Acute Myocardial Infarction.
6. β-lactam antibiotics: An overview from a medicinal chemistry perspective
7. Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its Drug Metabolism and Pharmacokinetics In Vitro Profile
8. Novel phosphatidylinositol 4-kinases III beta (PI4KIIIβ) inhibitors discovered by virtual screening using free energy models
9. Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats
10. LASSBio-596 protects gastric mucosa against the development of ethanol-induced gastric lesions in mice
11. Gastroprotective effects of N-acylarylhydrazone derivatives on ethanol-induced gastric lesions in mice are dependent on the NO/cGMP/KATP pathway
12. Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its DMPK Profile
13. Stereochemical insights into β-amino-N-acylhydrazones and their impact on DPP-4 inhibition
14. Potent immunosuppressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction
15. N-Acylhydrazones as drugs
16. The novel piperazine-containing compound LQFM018: Necroptosis cell death mechanisms, dopamine D4 receptor binding and toxicological assessment
17. Oxidative imbalance in mice intoxicated by microcystin-LR can be minimized
18. Structural characterization and cytotoxicity studies of different forms of a combretastatin A4 analogue
19. A combined experimental and in silico characterization to highlight additional structural features and properties of a potentially new drug
20. Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
21. Antiproliferative Activity of N -Acylhydrazone Derivative on Hepatocellular Carcinoma Cells Involves Transcriptional Regulation of Genes Required for G2/M Transition.
22. Abstract P2142: Evaluation Of Novel A3 Adenosine Receptor Agonist In Hypertension
23. Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes
24. A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives
25. Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent
26. Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor
27. Design, synthesis and in vitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives
28. N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity
29. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors
30. Design, synthesis, structural characterization and in vitro cytotoxic activity of mononuclear Ru(II)complexes
31. Hydrolysis of New Phthalimide-Derived Esters Catalyzed by Immobilized Lipase
32. Methyl Effect on the Metabolism, Chemical Stability, and Permeability Profile of Bioactive N-Sulfonylhydrazones
33. Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579
34. New oxidovanadium(IV) N-acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents
35. Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound
36. New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia
37. Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates
38. Discovery of naphthyl‐N‐acylhydrazone p38α MAPK inhibitors with in vivo anti‐inflammatory and anti‐TNF‐α activity
39. The antithrombotic and haemostatic effects of LASSBio‐752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats
40. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors
41. Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives
42. Abstract P2037: Activation Of A2A Adenosine Receptor Reduces Cardiac Dysfunction Resulting From Pulmonary Hypertension In Rats
43. Abstract P1054: Oral Administration Of New Agonist Of Adenosine Receptor Reduces Inflammatory Process And Cardiac Remodeling Induced By Myocardial Infarction In Rats
44. Discovery of Putative Dual Inhibitor of Tubulin and EGFR by Phenotypic Approach on LASSBio-1586 Homologs
45. New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis
46. LASSBio 596 per os avoids pulmonary and hepatic inflammation induced by microcystin-LR
47. Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation
48. Binuclear zinc(II) complexes with the anti-inflammatory compounds salicylaldehyde semicarbazone and salicylaldehyde-4-chlorobenzoyl hydrazone (H 2LASSBio-1064)
49. Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-Adrenergic receptor blocking properties
50. Structure-based design and biological profile of ( E)- N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of IκB kinase-β
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.